#EuroPCR #JACC LBCT: #FFR-guided complete #revascularization reduced future and repeated events compared with infarct-related artery only after 10 years. The risk was mainly driven by revasc, with no reduction in MIs or death. www.jacc.org/doi/10.1016/... #cvMI #revasc
10-Year Outcome of Complete or Infarct–Artery-Only Revascularization in STEMI with Multivessel Disease (DANAMI-3-PRIMULTI):
www.jacc.org
May 20, 2025 at 6:34 PM
#EuroPCR #JACC LBCT: #FFR-guided complete #revascularization reduced future and repeated events compared with infarct-related artery only after 10 years. The risk was mainly driven by revasc, with no reduction in MIs or death. www.jacc.org/doi/10.1016/... #cvMI #revasc
Great YIA presentation by ⭐️ Kelvin Supriami at #AHA24 of our data integrating @MGHHeartHealth cor angio data + Lp(a)
Very ⬆️ Lp(a) (>=175 nmol/L) associated w/ repeat angiography, ISR, revasc, & mortality after cath, + need for PCI after CABG, indept of baseline athero burden
#CardioSky #MedSky
Very ⬆️ Lp(a) (>=175 nmol/L) associated w/ repeat angiography, ISR, revasc, & mortality after cath, + need for PCI after CABG, indept of baseline athero burden
#CardioSky #MedSky
November 16, 2024 at 4:57 PM
Great YIA presentation by ⭐️ Kelvin Supriami at #AHA24 of our data integrating @MGHHeartHealth cor angio data + Lp(a)
Very ⬆️ Lp(a) (>=175 nmol/L) associated w/ repeat angiography, ISR, revasc, & mortality after cath, + need for PCI after CABG, indept of baseline athero burden
#CardioSky #MedSky
Very ⬆️ Lp(a) (>=175 nmol/L) associated w/ repeat angiography, ISR, revasc, & mortality after cath, + need for PCI after CABG, indept of baseline athero burden
#CardioSky #MedSky
What would be your approach?
1st cath lab for percutaneous revasc? 1st surgery and then percutaneous revasc? Or only surgery? As a surgeon: would you revasc? Ventriculoplasty?
1st cath lab for percutaneous revasc? 1st surgery and then percutaneous revasc? Or only surgery? As a surgeon: would you revasc? Ventriculoplasty?
November 10, 2024 at 10:23 AM
What would be your approach?
1st cath lab for percutaneous revasc? 1st surgery and then percutaneous revasc? Or only surgery? As a surgeon: would you revasc? Ventriculoplasty?
1st cath lab for percutaneous revasc? 1st surgery and then percutaneous revasc? Or only surgery? As a surgeon: would you revasc? Ventriculoplasty?
Deferral of coronary revasc by QFR was less safe than by standard FFR in the FAVOR III Europe trial - despite that QFR led to PCI in 21% more pts with intermediate stenosis.
eurointervention.pcronline.com/article/coro...
eurointervention.pcronline.com/article/coro...
January 5, 2025 at 1:25 AM
Deferral of coronary revasc by QFR was less safe than by standard FFR in the FAVOR III Europe trial - despite that QFR led to PCI in 21% more pts with intermediate stenosis.
eurointervention.pcronline.com/article/coro...
eurointervention.pcronline.com/article/coro...
3/2
what was completeness of revasc, and does that impact findings and how?
what was completeness of revasc, and does that impact findings and how?
January 20, 2025 at 8:18 PM
3/2
what was completeness of revasc, and does that impact findings and how?
what was completeness of revasc, and does that impact findings and how?
After SENIOR-RITA now a meta-analysis shows that elderly patients gain little from an early invasive strategy. Quite the contrary, they suffer from bleeding events and get repeat revasc.
#cardiosky
jamanetwork.com/journals/jam...
#cardiosky
jamanetwork.com/journals/jam...
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes
This systematic review and meta-analysis examines the association of an early invasive strategy vs a conservative strategy with clinical outcomes for patients 70 years or older who present with acute ...
jamanetwork.com
July 13, 2025 at 11:51 AM
After SENIOR-RITA now a meta-analysis shows that elderly patients gain little from an early invasive strategy. Quite the contrary, they suffer from bleeding events and get repeat revasc.
#cardiosky
jamanetwork.com/journals/jam...
#cardiosky
jamanetwork.com/journals/jam...
Indeed...I've quietly ignored the inherent bias when developing/assessing cTn based algorithms where cTn is part of the defn of the outcome. That's why I thought the revasc outcome was interesting. I'm not sure, though, how rates of revasc differ across jurisdictions?
April 8, 2025 at 8:47 PM
Indeed...I've quietly ignored the inherent bias when developing/assessing cTn based algorithms where cTn is part of the defn of the outcome. That's why I thought the revasc outcome was interesting. I'm not sure, though, how rates of revasc differ across jurisdictions?
I was referring to the recent negative trials on post-MI patients. They’re care - I guess with revasc, ldl-lowering, antiplatelets and hf-therapy if necessary - is already so good it’s hard to find new big improvements
November 18, 2024 at 9:29 AM
I was referring to the recent negative trials on post-MI patients. They’re care - I guess with revasc, ldl-lowering, antiplatelets and hf-therapy if necessary - is already so good it’s hard to find new big improvements
3/
ESPRIT (N=11255)
SBP delta 15.7 mmHg
PEP (CV death, MI, stroke, HF, revasc.): HR 0.88, 0.78-0.99
Stroke: 0.86, 0.73-1.02
Diabetic subgroup (N=4359)
PEP (CV death, MI, stroke, HF, revasc.): HR 0.91, 0.77-1.08
ESPRIT (N=11255)
SBP delta 15.7 mmHg
PEP (CV death, MI, stroke, HF, revasc.): HR 0.88, 0.78-0.99
Stroke: 0.86, 0.73-1.02
Diabetic subgroup (N=4359)
PEP (CV death, MI, stroke, HF, revasc.): HR 0.91, 0.77-1.08
November 16, 2024 at 3:07 PM
3/
ESPRIT (N=11255)
SBP delta 15.7 mmHg
PEP (CV death, MI, stroke, HF, revasc.): HR 0.88, 0.78-0.99
Stroke: 0.86, 0.73-1.02
Diabetic subgroup (N=4359)
PEP (CV death, MI, stroke, HF, revasc.): HR 0.91, 0.77-1.08
ESPRIT (N=11255)
SBP delta 15.7 mmHg
PEP (CV death, MI, stroke, HF, revasc.): HR 0.88, 0.78-0.99
Stroke: 0.86, 0.73-1.02
Diabetic subgroup (N=4359)
PEP (CV death, MI, stroke, HF, revasc.): HR 0.91, 0.77-1.08
#YesCCT did not improve outcomes for acute chest pain patients, but some subgroups would be interesting to analyze, almost 20% of subjects had prior revasc and while 22% had obstructive CAD on CCT, only 11% went on to cath www.nejm.org/doi/pdf/10.1... #ESCCongress
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain | NEJM
Many patients with suspected acute coronary syndrome in whom myocardial infarction has been ruled out in the emergency department remain at risk for cardiovascular events. Whether further investiga...
www.nejm.org
September 1, 2026 at 3:33 PM
#YesCCT did not improve outcomes for acute chest pain patients, but some subgroups would be interesting to analyze, almost 20% of subjects had prior revasc and while 22% had obstructive CAD on CCT, only 11% went on to cath www.nejm.org/doi/pdf/10.1... #ESCCongress
Se eu tô instável e vou fazer uma angioplastia ou revasc com chance de morrer é claro que eu também tomaria minha última coquinha
October 6, 2024 at 5:41 PM
Se eu tô instável e vou fazer uma angioplastia ou revasc com chance de morrer é claro que eu também tomaria minha última coquinha
One of many trials advocating for complete revasc in STEMI.
Questions remain:
- how to determine none-culprit: Visually, FFR, IVUS…?
- when to treat: immediately, index hospitalization, within 6 weeks…?
What’s your approach, #cardiosky?
Questions remain:
- how to determine none-culprit: Visually, FFR, IVUS…?
- when to treat: immediately, index hospitalization, within 6 weeks…?
What’s your approach, #cardiosky?
In STEMI patients with multivessel CAD, complete revascularization vs culprit lesion-only PCI significantly enhances angina-related quality of life, showing the benefits of broader intervention. #Angina #Cardiology PMID:36129696, JAMA Cardiol 2022 doi.org/10.1001/jama...
Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Quality of Life in Patients With STEMI
This secondary analysis of a randomized clinical trial determines whether complete revascularization improves angina status in patients with ST-segment elevation myocardial infarction (STEMI) and mult...
doi.org
January 3, 2025 at 11:54 AM
One of many trials advocating for complete revasc in STEMI.
Questions remain:
- how to determine none-culprit: Visually, FFR, IVUS…?
- when to treat: immediately, index hospitalization, within 6 weeks…?
What’s your approach, #cardiosky?
Questions remain:
- how to determine none-culprit: Visually, FFR, IVUS…?
- when to treat: immediately, index hospitalization, within 6 weeks…?
What’s your approach, #cardiosky?
- Primary outcome (any revasc) is pragmatic and might represent what's interesting for emergency physicians, but might not be independent of the tests used
- Study population (anyone with ECG available) might not really be the target population of interest.
2/n
- Study population (anyone with ECG available) might not really be the target population of interest.
2/n
April 8, 2025 at 8:13 AM
- Primary outcome (any revasc) is pragmatic and might represent what's interesting for emergency physicians, but might not be independent of the tests used
- Study population (anyone with ECG available) might not really be the target population of interest.
2/n
- Study population (anyone with ECG available) might not really be the target population of interest.
2/n
#MetaAnalysis: #Ticagrelor #DAPT post-PCI in CCS ↓ MACE, mortality & revasc vs clopidogrel but ↑ minor bleeding. Strongest in Ticagrelor & Asian cohorts. Personalized therapy key. #PCI @ashkanabdollahi.bsky.social @bakhshihooman.bsky.social link.springer.com/article/10.1...
The efficacy and safety of ticagrelor and prasugrel versus clopidogrel in post-PCI dual antiplatelet therapy in chronic coronary syndrome: a systematic review and meta-analysis - BMC Cardiovascular Di...
BMC Cardiovascular Disorders - Clopidogrel is the guideline-recommended P2Y12 inhibitor for dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in Chronic Coronary...
link.springer.com
May 5, 2026 at 11:00 AM
#MetaAnalysis: #Ticagrelor #DAPT post-PCI in CCS ↓ MACE, mortality & revasc vs clopidogrel but ↑ minor bleeding. Strongest in Ticagrelor & Asian cohorts. Personalized therapy key. #PCI @ashkanabdollahi.bsky.social @bakhshihooman.bsky.social link.springer.com/article/10.1...
In my simplistic concept MI outcome is mostly dependent on early presentation and revasc. If that doesn’t go so well, the patient enters heart failure territory where EF-based OMT is well established. This of course neglects the specifics of ischemic heart disease like pro-arrhythmia/remodeling.
February 8, 2026 at 10:13 PM
In my simplistic concept MI outcome is mostly dependent on early presentation and revasc. If that doesn’t go so well, the patient enters heart failure territory where EF-based OMT is well established. This of course neglects the specifics of ischemic heart disease like pro-arrhythmia/remodeling.
revasc was equal in both arms (which is the only thing that had effect on PET scans)
which sort of underscores that it's that plaque stabilization and not the ischemia (which, well, we already knew). The low CFR's were markers of disease severity. Once again though confused for causation.
which sort of underscores that it's that plaque stabilization and not the ischemia (which, well, we already knew). The low CFR's were markers of disease severity. Once again though confused for causation.
February 1, 2026 at 1:15 AM
revasc was equal in both arms (which is the only thing that had effect on PET scans)
which sort of underscores that it's that plaque stabilization and not the ischemia (which, well, we already knew). The low CFR's were markers of disease severity. Once again though confused for causation.
which sort of underscores that it's that plaque stabilization and not the ischemia (which, well, we already knew). The low CFR's were markers of disease severity. Once again though confused for causation.
3) The CLEAR SYNERGY trial of 7062pts also showed use of colchicine after MI and continued for a median of 3 yrs did not reduce a composite of CV death, MI, CVA or unplanned coronary revasc
Link: www.nejm.org/doi/full/10....
#CardioSky
4/11
Link: www.nejm.org/doi/full/10....
#CardioSky
4/11
Colchicine in Acute Myocardial Infarction | NEJM
Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 fac...
www.nejm.org
November 18, 2024 at 10:24 PM
3) The CLEAR SYNERGY trial of 7062pts also showed use of colchicine after MI and continued for a median of 3 yrs did not reduce a composite of CV death, MI, CVA or unplanned coronary revasc
Link: www.nejm.org/doi/full/10....
#CardioSky
4/11
Link: www.nejm.org/doi/full/10....
#CardioSky
4/11
We did surgery 1st, without revasc. Resolved tamponade. Contained LV free wall rupture. Glued a pericardial patch to the LV defect.
November 10, 2024 at 10:23 AM
We did surgery 1st, without revasc. Resolved tamponade. Contained LV free wall rupture. Glued a pericardial patch to the LV defect.
🚨 2025 ACS Guidelines,What's new? 🩺💊
🩸 DAPT: Ticagrelor/prasugrel >Clopidogrel
📉 LDL: Statins + Ezetimibe,PCSK9i if ≥70
🔬 PCI: Radial > Femoral, complete revasc
❤️ Revascularization: Complete for STEMI/NSTE-ACS
🏃♂️ Prevention: Lipids,Cardiac Rehab
youtu.be/MpNwaTA0ebw?... @amermedicalassn.bsky.social
🩸 DAPT: Ticagrelor/prasugrel >Clopidogrel
📉 LDL: Statins + Ezetimibe,PCSK9i if ≥70
🔬 PCI: Radial > Femoral, complete revasc
❤️ Revascularization: Complete for STEMI/NSTE-ACS
🏃♂️ Prevention: Lipids,Cardiac Rehab
youtu.be/MpNwaTA0ebw?... @amermedicalassn.bsky.social
🔬 Breaking Down the 2025 ACS Guidelines: What’s New? 💉📉
YouTube video by MasterMedFacts
youtu.be
February 28, 2025 at 7:33 PM
🚨 2025 ACS Guidelines,What's new? 🩺💊
🩸 DAPT: Ticagrelor/prasugrel >Clopidogrel
📉 LDL: Statins + Ezetimibe,PCSK9i if ≥70
🔬 PCI: Radial > Femoral, complete revasc
❤️ Revascularization: Complete for STEMI/NSTE-ACS
🏃♂️ Prevention: Lipids,Cardiac Rehab
youtu.be/MpNwaTA0ebw?... @amermedicalassn.bsky.social
🩸 DAPT: Ticagrelor/prasugrel >Clopidogrel
📉 LDL: Statins + Ezetimibe,PCSK9i if ≥70
🔬 PCI: Radial > Femoral, complete revasc
❤️ Revascularization: Complete for STEMI/NSTE-ACS
🏃♂️ Prevention: Lipids,Cardiac Rehab
youtu.be/MpNwaTA0ebw?... @amermedicalassn.bsky.social
"We know that we have to pursue complete revasc in a STEMI patient. What we don’t know is how” says Simone Biscaglia. Angiography? Physiology? AIR-STEMI results indicate that angiography-derived FFR guidance improves outcomes compared to conventional angiography alone.
www.tctmd.com/news/air-ste...
www.tctmd.com/news/air-ste...
AIR-STEMI: Angiography-Derived FFR Informs Complete PCI in STEMI
The study supports a strategy of going wire-free for functional assessment in this setting and may well be “practice changing.”
www.tctmd.com
September 2, 2026 at 10:59 AM
"We know that we have to pursue complete revasc in a STEMI patient. What we don’t know is how” says Simone Biscaglia. Angiography? Physiology? AIR-STEMI results indicate that angiography-derived FFR guidance improves outcomes compared to conventional angiography alone.
www.tctmd.com/news/air-ste...
www.tctmd.com/news/air-ste...
New issue of #VMJ is now online:
- Life's Essential 8 score & vascular function
- Cilostazol use & calf muscle pathophys in PAD
- Carotid revasc practice patterns
- Core curriculum: carotid duplex US
- Review: HD access
- Patient page: renal denervation
journals.sagepub.com/toc/VMJ/curr...
- Life's Essential 8 score & vascular function
- Cilostazol use & calf muscle pathophys in PAD
- Carotid revasc practice patterns
- Core curriculum: carotid duplex US
- Review: HD access
- Patient page: renal denervation
journals.sagepub.com/toc/VMJ/curr...
August 17, 2026 at 1:01 PM
New issue of #VMJ is now online:
- Life's Essential 8 score & vascular function
- Cilostazol use & calf muscle pathophys in PAD
- Carotid revasc practice patterns
- Core curriculum: carotid duplex US
- Review: HD access
- Patient page: renal denervation
journals.sagepub.com/toc/VMJ/curr...
- Life's Essential 8 score & vascular function
- Cilostazol use & calf muscle pathophys in PAD
- Carotid revasc practice patterns
- Core curriculum: carotid duplex US
- Review: HD access
- Patient page: renal denervation
journals.sagepub.com/toc/VMJ/curr...
That’s blasphemy where I work.
I’d go one further and say angina->anti-anginals->ccta->revasc for refractory angina/prognostically sig disease. Plenty of microvascular angina cases that don’t get highlighted by ct
I’d go one further and say angina->anti-anginals->ccta->revasc for refractory angina/prognostically sig disease. Plenty of microvascular angina cases that don’t get highlighted by ct
January 13, 2026 at 10:36 AM
That’s blasphemy where I work.
I’d go one further and say angina->anti-anginals->ccta->revasc for refractory angina/prognostically sig disease. Plenty of microvascular angina cases that don’t get highlighted by ct
I’d go one further and say angina->anti-anginals->ccta->revasc for refractory angina/prognostically sig disease. Plenty of microvascular angina cases that don’t get highlighted by ct
Sempre fico com medo de ser alguma coisa com a minha tia que fez a revasc lá, mas dá última vez foi uma R- perguntando se eu não era sobrinha de uma fulana que não tem o nome da minha tia. Veremos o que é dessa vez.
September 16, 2024 at 12:35 AM
Sempre fico com medo de ser alguma coisa com a minha tia que fez a revasc lá, mas dá última vez foi uma R- perguntando se eu não era sobrinha de uma fulana que não tem o nome da minha tia. Veremos o que é dessa vez.
Open Access UCL Research: Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC)
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC)
-
...
UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
discovery.ucl.ac.uk
March 18, 2026 at 10:36 AM
Open Access UCL Research: Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC)
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
Compared with DES, use of DCBs as an alternative for treating de novo CAD was associated with a significantly ⬆️ rate of CV death, TV-MI and target lesion revasc at 3 years. Read more from REC-CAGEFREE 1: https://bit.ly/47tF8sL
#JACC #TCT2025 #CardioSky #MedSky
#JACC #TCT2025 #CardioSky #MedSky
October 27, 2025 at 10:15 PM
Compared with DES, use of DCBs as an alternative for treating de novo CAD was associated with a significantly ⬆️ rate of CV death, TV-MI and target lesion revasc at 3 years. Read more from REC-CAGEFREE 1: https://bit.ly/47tF8sL
#JACC #TCT2025 #CardioSky #MedSky
#JACC #TCT2025 #CardioSky #MedSky